Neil A Fanger
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$21.0MFederal grants as PI44 awards
0Patents grantedNone matched
23Papers3,451 citations
Federal awards and patents by year
AwardsPatents
44 awards · $21.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 2, 2026 | NIH | SBIR Phase I A Novel Preventative and Treatment for Klebsiella Pneumoniae Infection | $307K | VIRTICI LLC |
| Aug 26, 2026 | NIH | SBIR Phase II A Bioengineered Probiotic for Resetting Immune Function in Rheumatoid Arthritis | $306K | VIRTICI LLC |
| Aug 13, 2026 | NIH | SBIR Phase II A Novel Immune-modulating Probiotic for Treating Rheumatoid Arthritis | $300K | VIRTICI LLC |
| Jun 1, 2026 | NIH | SBIR Phase II A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | $904K | VIRTICI LLC |
| Aug 6, 2025 | NIH | SBIR Phase II A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection | $699K | VIRTICI LLC |
| Apr 11, 2025 | NIH | SBIR Phase II A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | $1000K | VIRTICI LLC |
| Sep 19, 2024 | NIH | SBIR Phase II A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection | $924K | VIRTICI LLC |
| Aug 15, 2024 | NIH | SBIR Phase I A Novel Blood Test for Early Diagnosis of Frontotemporal Lobar Degeneration | $700K | VIRTICI LLC |
| Jun 14, 2024 | NIH | SBIR Phase II A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | $1.0M | VIRTICI LLC |
| Mar 22, 2024 | NIH | SBIR Phase I A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection | $307K | VIRTICI LLC |
| Aug 2, 2023 | NIH | SBIR Phase I A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease | $257K | VIRTICI LLC |
| Aug 1, 2023 | NIH | SBIR Phase I A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease | $281K | VIRTICI LLC |
| Jul 31, 2023 | NIH | SBIR Phase I A Novel Small Molecule for the Treatment of Periodontitis | $306K | VIRTICI LLC |
| Jun 16, 2023 | NIH | SBIR Phase II A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance | $979K | VIRTICI LLC |
| Apr 19, 2023 | NIH | SBIR Phase I A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection | $307K | VIRTICI LLC |
| Apr 5, 2023 | NIH | SBIR Phase I A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease | $216K | VIRTICI LLC |
| Mar 28, 2023 | NIH | SBIR Phase II A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | $306K | VIRTICI LLC |
| Sep 19, 2022 | NIH | SBIR Phase I A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease | $441K | VIRTICI LLC |
| Aug 29, 2022 | NIH | SBIR Phase I A Novel Small Molecule for the Treatment of Periodontitis | $306K | VIRTICI LLC |
| Aug 22, 2022 | NIH | SBIR Phase I A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease | $73K | VIRTICI LLC |
| Aug 19, 2022 | NIH | SBIR Phase I A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease | $292K | VIRTICI LLC |
| Jul 8, 2022 | NIH | SBIR Phase II A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance | $980K | VIRTICI LLC |
| Mar 31, 2022 | NIH | SBIR Phase I A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease | $30K | VIRTICI LLC |
| Mar 20, 2022 | NIH | SBIR Phase II A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | $306K | VIRTICI LLC |
| Sep 21, 2021 | NIH | SBIR Phase I A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease | $412K | VIRTICI LLC |
| Jul 14, 2021 | NIH | SBIR Phase II A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance | $994K | VIRTICI LLC |
| Jan 21, 2021 | NIH | SBIR Phase I A Novel LIGHT/TL1A Bispecific Antibody for the Treatment of Fibrotic Diseases | $299K | VIRTICI LLC |
| Jan 11, 2021 | NIH | SBIR Phase I A Novel Probiotic-Based Nanobody Delivery Platform | $281K | VIRTICI LLC |
| Jun 15, 2020 | NIH | SBIR Phase I A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients | $159K | VIRTICI LLC |
| Apr 28, 2020 | NIH | SBIR Phase II A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance | $300K | VIRTICI LLC |
| Jan 25, 2020 | NIH | SBIR Phase I A Novel Probiotic-Based Nanobody Delivery Platform | $300K | VIRTICI LLC |
| Jul 10, 2019 | NIH | SBIR Phase I A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients | $300K | VIRTICI LLC |
| Jun 28, 2018 | NIH | SBIR Phase II A Novel Tolerance Therapeutic for Treating Graves' Disease | $300K | VIRTICI LLC |
| Apr 30, 2018 | NIH | SBIR Phase II A Novel Peptide Therapeutic for Obesity | $829K | VIRTICI LLC |
| Mar 15, 2018 | NIH | SBIR Phase II A Novel Tolerance Therapeutic for Treating Multiple Sclerosis | $990K | VIRTICI LLC |
| Sep 14, 2017 | NIH | SBIR Phase I A Novel Tolerance Therapeutic for Treating Type 1 Diabetes | $300K | VIRTICI LLC |
| Aug 1, 2017 | NIH | SBIR Phase I A Novel Probiotic for the Treatment of Rheumatoid Arthritis | $225K | VIRTICI LLC |
| Aug 1, 2017 | NIH | SBIR Phase I A Novel Tolerance-inducing Probiotic Platform | $300K | VIRTICI LLC |
| May 1, 2017 | NIH | SBIR Phase II A Novel Peptide Therapeutic for Obesity | $1.0M | VIRTICI LLC |
| Apr 21, 2017 | NIH | SBIR Phase II A Novel Tolerance Therapeutic for Treating Multiple Sclerosis | $1.0M | VIRTICI LLC |
| Aug 2, 2016 | NIH | SBIR Phase I A Novel Probiotic for the Treatment of Sjogren's Syndrome | $225K | VIRTICI LLC |
| Apr 14, 2016 | NIH | SBIR Phase II A Novel Tolerance Therapeutic for Treating Multiple Sclerosis | $480K | VIRTICI LLC |
| Sep 21, 2015 | NIH | SBIR Phase I A Novel Therapeutic Peptide for Treating Stroke | $434K | VIRTICI LLC |
| Feb 26, 2015 | NIH | SBIR Phase I A Novel Tolerance Therapeutic for Treating Peanut Allergy | $319K | VIRTICI LLC |
1 patents as inventor
- US VIRTICI LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#3
Awards as PI#1
Patents#273
Companies
- VIRTICI LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.